Sanofi(US:SNY) Globenewswireยท2025-10-20 05:00Core Insights - Sanofi's high-dose influenza vaccine, Efluelda (Fluzone High-Dose in North America), shows significantly reduced hospitalization risk for adults aged 65 and older compared to standard-dose vaccines, as evidenced by the FLUNITY-HD study [1][4][3] Study Overview - The FLUNITY-HD study is the largest of its kind, involving nearly half a million participants across multiple seasons and geographic areas, demonstrating the effectiveness of the high-dose vaccine [4][6][5] - The study utilized individual randomization in real-world settings, providing robust evidence for the vaccine's efficacy [2][6] Key Findings - Efluelda/Fluzone High-Dose demonstrated a 31.9% additional reduction in laboratory-confirmed influenza hospitalizations compared to standard-dose vaccines [4][7] - The vaccine also provided 8.8% additional protection against pneumonia/influenza hospitalizations and 6.3% additional reduction in hospitalizations for cardio-respiratory events [4][7] - For every 515 older adults vaccinated with the high-dose vaccine, one all-cause hospitalization is prevented, highlighting its potential to improve quality of life for vulnerable seniors [3][4] Implications for Public Health - The findings suggest that the high-dose vaccine could reshape public health strategies and clinical guidelines, particularly for older adults who are at higher risk for severe influenza-related complications [2][3] - Preventing influenza hospitalizations may lead to societal benefits, including lower healthcare costs and reduced pressure on medical systems [3][4] Product Information - Efluelda is specifically designed for adults aged 60 and older in Europe and for those aged 65 and older in North America, containing four times the antigen of a standard-dose vaccine to enhance immune response [8][9]